

Volume 537
October 15, 1988

THE MESOCORTICOLIMBIC DOPAMINE SYSTEM^a

Editors and Conference Organizers

PETER W. KALIVAS and CHARLES B. NEMEROFF

CONTENTS

Preface. By PETER W. KALIVAS and CHARLES B. NEMEROFF	xi
--	----

Part I. Anatomy and Electrophysiology

Topographic Organization of Ascending Dopaminergic Projections. By JAMES H. FALLON	1
Neuroanatomical Organization of Dopamine Neurons in the Ventral Tegmental Area. By VALERIE B. DOMESICK	10
Telencephalic Projections of the A8 Dopamine Cell Group. By ARIEL Y. DEUTCH, MENEK GOLDSTEIN, FRANK BALDINO, JR., and ROBERT H. ROTH	27
<i>In Vivo</i> and <i>In Vitro</i> Intracellular Recordings from Rat Midbrain Dopamine Neurons. By ANTHONY A. GRACE	51
Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Midbrain Dopamine Neurons. By BENJAMIN S. BUNNEY	77
Influence of Dopamine on Limbic Inputs to the Nucleus Accumbens. By G. J. MOGENSEN, C. R. YANG, and C. Y. YIM	86
Influence of the Mesocortical/Prefrontal Dopamine Neurons on Their Target Cells. By A. M. THIERRY, J. MANTZ, C. MILLA, and J. GLOWINSKI	101

Part II. Neurochemical Properties

Heterologous Regulation of Receptors on Target Cells of Dopamine Neurons in the Prefrontal Cortex, Nucleus Accumbens, and Striatum. By J. GLOWINSKI, D. HERVÉ, and J. P. TASSIN	112
An <i>in Vivo</i> Voltammetric Study of the Response of Mesocortical and Mesoaccumbens Dopaminergic Neurons to Environmental Stimuli in Strains of Rats with Differing Levels of Emotionality. By BERNARD SCATTON, MAGALI D'ANGIO, PETER DRISCOLL, and ANDRÉ SERRANO	124

^a This volume is the result of a conference entitled The Mesocorticolimbic Dopamine System held by the New York Academy of Sciences in Miami, Florida on May 4-6, 1987.

Stress and the Mesocorticolimbic Dopamine Systems. <i>By</i> ROBERT H. ROTH, SEE-YING TAM, YOSHISHIGE I-TA, JING-XIA YANG, and ARIEL Y. DEUTCH ...	138
Intracerebral Transplantation of Dopamine Neurons: Understanding the Functional Role of the Mesolimbocortical Dopamine System and Developing a Therapy for Parkinson's Disease. <i>By</i> P. BRUNDIN, R. E. STRECKER, F. H. GAGE, O. LINDVALL, and A. BJÖRKLUND	148
Neurotoxicity in Dopamine and 5-Hydroxytryptamine Terminal Fields: A Regional Analysis in Nigrostriatal and Mesolimbic Projections. <i>By</i> L. S. SEIDEN, D. L. COMMINS, G. VOSMER, K. AXT, and G. MAREK	161
The Biochemistry and Pharmacology of Mesoamygdaloid Dopamine Neurons. <i>By</i> CLINTON D. KILTS, CARL M. ANDERSON, TIMOTHY D. ELY, and RICHARD B. MAILMAN	173
Stress-Related Activation of Cerebral Dopaminergic Systems. <i>By</i> ADRIAN J. DUNN	188

Part III. Behavioral Properties

Mesocorticolimbic Dopamine Systems and Reward. <i>By</i> H. C. FIBIGER and A. G. PHILLIPS	206
The Functional Output of the Mesolimbic Dopamine System. <i>By</i> GEORGE F. KOOB and NEAL R. SWERDLOW	216
Psychomotor Stimulant Properties of Addictive Drugs. <i>By</i> ROY A. WISE ...	228
Mesencephalic Dopaminergic Neurons: Role in the General Economy of the Brain. <i>By</i> HÉRVÉ SIMON and MICHEL LE MOAL	235
Relationships between Mesolimbic Dopamine Function and Eating Behavior. <i>By</i> GERARD P. SMITH and LINDA H. SCHNEIDER	254
Stress and Enhanced Dopamine Utilization in the Frontal Cortex: The Myth and the Reality. <i>By</i> SEYMOUR M. ANTELMAN, STEVEN KNOFF, ANTHONY R. CAGGIULA, DONNA KOCAN, DONALD T. LYSLE, and DAVID J. EDWARDS	262

Part IV. Clinical Medicine (I)

Neuropeptides, Dopamine, and Schizophrenia. <i>By</i> CHARLES B. NEMEROFF and GARTH BISSETTE	273
Cocaine-Induced Behavioral Sensitization and Kindling: Implications for the Emergence of Psychopathology and Seizures. <i>By</i> ROBERT M. POST, SUSAN R. B. WEISS, and AGU PERT	292
A Critical Appraisal of CSF Monoamine Metabolite Studies in Schizophrenia. <i>By</i> ERIK WIDERLÖF	309
Dopamine Receptor Sensitivity Changes with Chronic Stimulants. <i>By</i> TONG H. LEE, EVERETT H. ELLINWOOD, JR., and J. KEN NISHITA	324
Mesocortical Dopaminergic Function and Human Cognition. <i>By</i> DANIEL R. WEINBERGER, KAREN FAITH BERMAN, and THOMAS N. CHASE	330
Plasma Homovanillic Acid as an Index of Central Dopaminergic Activity: Studies in Schizophrenic Patients. <i>By</i> DAVID PICKAR, ALAN BREIER, and JOHN KELSE	339

Part V. Co-localization and Interactions

Interactions between Mesolimbic Dopamine Neurons, Cholecystokinin, and Neurotensin: Evidence Using <i>in Vivo</i> Voltammetry. By ANTHONY G. PHILLIPS, CHARLES D. BLAHA, HANS C. FIBIGER, and ROSS F. LANE	347
Cholecystokinin, Dopamine, and Schizophrenia: Recent Progress and Current Problems. By REX Y. WANG	362
Modulation of Mesolimbic Dopaminergic Behaviors by Cholecystokinin. By JACQUELINE N. CRAWLEY	380
Neurotensin and the Mesocorticolimbic Dopamine System. By GARTH BISSETTE and CHARLES B. NEMEROFF	397
Enkephalin Modulation of A10 Dopamine Neurons: A Role in Dopamine Sensitization. By PETER W. KALIVAS, PATRICIA DUFFY, ROGER DILTS, and RAYMOND ABHOLD	405
Behavioral Evidence for Differential Neuropeptide Modulation of the Mesolimbic Dopamine System. By ANN E. KELLEY and MARTINE CADOR	415

Part VI. Clinical Medicine (II)

Neuroleptic Binding to Human Brain Receptors: Relation to Clinical Effects. By ELLIOTT RICHELSON	435
Dopamine Neuronal Tracts in Schizophrenia: Their Pharmacology and <i>in Vivo</i> Glucose Metabolism. By CAROL A. TAMMINGA, G. HOWARD BURROWS, THOMAS N. CHASE, LARRY D. ALPHS, and GUNVANT K. THAKER	443
MPTP Effects on Dopamine Neurons. By IRWIN J. KOPIN	451
The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression. By ALAN F. SCHATZBERG and ANTHONY J. ROTHCHILD	462

Part VII. Poster Papers

Localization of Mu Opioid and Neurotensin Receptors with the A10 Region of the Rat. By R. P. DILTS and P. W. KALIVAS	472
Inhibition of Endogenous Dopamine Release from the Ventromedial Mesencephalon after Daily Cocaine or Morphine. By PATRICIA DUFFY and PETER W. KALIVAS	475
Effects of Neurotensin on Dopamine Release in the Nucleus Accumbens: Comparisons with Atypical Antipsychotic Drug Action. By CHARLES D. BLAHA, ANTHONY G. PHILLIPS, HANS C. FIBIGER, and ROSS F. LANE	478
Effects of Chronic Neuroleptic Administration on Nigrostriatal and Mesocorticolimbic Dopamine Release: Analysis Using <i>in Vivo</i> Voltammetry. By ROSS F. LANE and CHARLES D. BLAHA	481
<i>In Situ</i> Hybridization Histochemistry of Tyrosine Hydroxylase Messenger RNA in Rat Brain. By FRANK BALDINO, JR., ARIEL Y. DEUTCH, ROBERT H. ROTH, and MICHAEL E. LEWIS	484

Neurotensin Stimulates the Phosphorylation of Caudate Nucleus Synaptosomal Proteins. By SCOTT T. CAIN, MURRAY ABRAMSON, and CHARLES B. NEMEROFF	488
Facilitory and Inhibitory Effects of Nucleus Accumbens Amphetamine on Feeding. By LOIS M. COLLE and ROY A. WISE	491
Influence of Neurotensin on Endogenous Dopamine Release from Explanted Mesoaccumbens Neurons <i>in Vitro</i> : Selective Activation of Somatodendritic Receptor Sites. By M. DUFF DAVIS and CLINTON D. KILTS	493
Intra-Accumbens Injection of Neurotensin Antagonizes the Behavioral Supersensitivity to L-DOPA in Dopamine-Denervated Rats. By GREGORY N. ERVIN and CHARLES B. NEMEROFF	496
Regulation of Mesolimbic Dopamine Tracts by Cyclo(Leu-Gly). By J. Z. FIELDS, R. SAMI, J. M. LEE, F. DELEON-JONES, and R. F. RITZMANN	498
Effects of Phencyclidine on Ventral Tegmental A10 Dopamine Neurons in Rats with Lesions of the Prefrontal Cortex, Accumbens, and Dorsal Raphe Nuclei. By ANGELO CECI and EDWARD D. FRENCH	500
Anatomically Selective Action of Atypical Neuroleptics on the Mesocorticolimbic Dopamine System. By ELIOT L. GARDNER and THOMAS F. SEEGER	502
Electrical Stimulation of Medial Prefrontal and Cingulate Cortex Elicits Bursting in a Small Population of Mesencephalic Dopamine Neurons. By R. F. GARIANO and P. M. GROVES	505
Microdialysis in the Nucleus Accumbens during Feeding or Drugs of Abuse: Amphetamine, Cocaine, and Phencyclidine. By LUIZ HERNANDEZ, FRANCIS LEE, and BARTLEY G. HOEBEL	508
The Effect of Isolation Rearing and Stress on Monoamines in Forebrain Nigrostriatal, Mesolimbic, and Mesocortical Dopamine Systems. By R. R. HOLSON, S. F. ALI, and A. C. SCALLET	512
Alterations in Neurotensin- and Bombesin-like Immunoreactivity in MPTP-Treated Mice. By BETH LEVANT, GARTH BISSETTE, YUKA-MARIE PARKER, and CHARLES B. NEMEROFF	515
Neuropsychological Correlates of Early Parkinson's Disease: Evidence for Frontal Lobe Dysfunction. By BONNIE E. LEVIN, MARIA M. LLABRE, and WILLIAM J. WEINER	518
Distinct Dopamine Terminal Areas Controlling Behavioral Activation and Reward Value of Hypothalamic Stimulation. By DARRYL NEILL	520
Increased Motivation to Self-Administer Apomorphine following 6-Hydroxydopamine Lesions of the Nucleus Accumbens. By DAVID C. S. ROBERTS and G. VICKERS	523
A Study of the Interactions of Pimozide, Morphine, and Muscimol on Brain Stimulation Reward: Behavioral Evidence for Depolarization Inactivation of A10 Dopaminergic Neurons. By PIERRE-PAUL ROMPRÉ and ROY A. WISE	525
Pharmacology of Dopamine-Induced Electrophysiological Responses in the Rat Prefrontal Cortex: D ₁ - or D ₂ -Mediated? By SUSAN R. SESACK and BENJAMIN S. BUNNEY	529

Rat Mesocortical Dopaminergic Neurons Are Mixed Neurotensin/ Dopamine Neurons: Immunohistochemical and Biochemical Evidence. By J. P. TASSIN, P. KITABGI, G. TRAMU, J. M. STUDLER, D. HERVÉ, F. TROVERO, and J. GLOWINSKI	531
Comparison of the Effects of Selective D ₁ and D ₂ Receptor Antagonists on Sucrose Sham Feeding and Water Sham Drinking. By L. H. SCHNEIDER, D. GREENBERG, and G. P. SMITH	534
Index of Contributors	539

Major funding was provided by:

- NATIONAL INSTITUTE OF MENTAL HEALTH/NIH
- NATIONAL INSTITUTE OF DRUG ABUSE/NIH

Additional financial assistance was received from:

- ABBOTT LABORATORIES
- ASTRA ALAB AB
- AYERST LABORATORIES
- BERLEX LABORATORIES INC.
- BRISTOL-MEYERS COMPANY
- ELI LILLY AND COMPANY
- HOECHST-ROUSSEL
- HOFFMANN-LAROCHE INC.
- LOREX INC.
- McNEIL PHARMACEUTICAL
- MERCK SHARP AND DOHME RESEARCH LABORATORIES
- MILES LABORATORIES, INC./BAYER AG
- NATIONAL SCIENCE FOUNDATION
- OFFICE OF NAVAL RESEARCH, DEPARTMENT OF THE NAVY
- PFIZER CENTRAL RESEARCH
- SEARLE RESEARCH AND DEVELOPMENT
- SCHERING CORPORATION
- THE COCA-COLA COMPANY
- THE UPJOHN COMPANY

The New York Academy of Sciences believes that it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the participants in the reported conferences are their own and not necessarily those of the Academy. The Academy has no intent to influence legislation by providing such forums.